Project Grant R01HL179505
Award Date 7/15/26
Completion Date 3/31/31
Dollars Obligated $613K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Birmingham, AL 35205, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham a Project Grant of $535,556 under the Cardiovascular Diseases Research program (CFDA 93.837) effective August 1, 2025, with completion targeted for May 31, 2030. This award supports research to elucidate the role of a novel mechanosensitive histone modification (H3T32 O-GlcNAc) in atherosclerosis pathogenesis. The research investigates how atheroprone shear stress...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham $1,254,849 on September 16, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research aimed at improving cardiac microenvironment treatment strategies for diabetic ischemic heart failure (IHF). The project, scheduled for completion by June 30, 2029, focuses on developing engineered approaches to modify small extracellular...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $166,644 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on July 16, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports research investigating inflammatory responses in human hematopoietic stem cells (HSCs) with a focus on understanding how aging and clonal hematopoiesis—specifically TET2 mutations—alter...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Alabama at Birmingham $158,572 on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a five-year project through August 31, 2030. This Project Grant funds the development of genotypic and phenotypic approaches to subtype individuals with coronary heart disease (CHD), with emphasis on patients who develop CHD without elevated traditional risk...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $549,128 under the Cardiovascular Diseases Research program (CFDA 93.837) to The Research Foundation for the State University of New York to conduct a longitudinal investigation of biological aging in early life and its relationship to atherosclerosis development. The project, initiated August 15, 2025, with completion targeted for May 31, 2030, examines how developmental and environmental factors shape...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $1,072,936 to the University of California, San Diego, effective September 15, 2025, through June 30, 2029, under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports fundamental research investigating protein aggregation mechanisms in hematopoietic stem cells (HSCs), with the primary deliverable being scientific research and discovery designed to advance...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Vanderbilt University Medical Center a $3.04 million Project Grant on August 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the intersection of immunity and cardiovascular disease through August 2030. The award supports two primary research projects designed to elucidate how immune cell activation contributes to organ damage in hypertension and autoimmune diseases....
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of California, Los Angeles a $1.56 million Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective July 15, 2026, with completion targeted for March 31, 2028. This award funds basic science research to elucidate the role of noncoding RNA—specifically long noncoding RNAs (lncRNAs) and micropeptides—in cardiovascular disease pathogenesis, with emphasis on lipid metabolism,...
- Federal Grant Award Summary Vanderbilt University Medical Center received a $158,544 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025 through July 31, 2030. This award supports research aimed at identifying high-risk TET2 (Ten-Eleven Translocation methylcytosine dioxygenase 2) mutations associated with clonal hematopoiesis of indeterminate potential (CHIP) and its role in...
- Federal Grant Award Summary The University of Virginia received a $117,552 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded January 4, 2026, with completion targeted for June 30, 2027. The research investigates the role of lymphatic endothelial alpha globin (HBA) in cardiometabolic heart failure (CMHF), a condition affecting over three million Americans and frequently associated with obesity, type...